Xencor (XNCR) Competitors $9.31 +0.07 (+0.71%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. APLS, XENE, NAMS, GMTX, BHC, AGIO, TWST, INDV, RXRX, and DNLIShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), Indivior (INDV), Recursion Pharmaceuticals (RXRX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Apellis Pharmaceuticals Xenon Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics Bausch Health Cos Agios Pharmaceuticals Twist Bioscience Indivior Recursion Pharmaceuticals Denali Therapeutics Xencor (NASDAQ:XNCR) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Which has more risk and volatility, XNCR or APLS? Xencor has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Do institutionals & insiders have more ownership in XNCR or APLS? 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 4.8% of Xencor shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend XNCR or APLS? Xencor presently has a consensus target price of $28.00, indicating a potential upside of 200.88%. Apellis Pharmaceuticals has a consensus target price of $40.00, indicating a potential upside of 103.86%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Does the media prefer XNCR or APLS? In the previous week, Apellis Pharmaceuticals had 10 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Apellis Pharmaceuticals and 1 mentions for Xencor. Xencor's average media sentiment score of 1.89 beat Apellis Pharmaceuticals' score of 0.61 indicating that Xencor is being referred to more favorably in the media. Company Overall Sentiment Xencor Very Positive Apellis Pharmaceuticals Positive Which has stronger valuation & earnings, XNCR or APLS? Apellis Pharmaceuticals has higher revenue and earnings than Xencor. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$127.23M5.21-$232.62M-$3.06-3.04Apellis Pharmaceuticals$775.84M3.18-$197.88M-$1.79-10.96 Is XNCR or APLS more profitable? Apellis Pharmaceuticals has a net margin of -28.83% compared to Xencor's net margin of -181.17%. Xencor's return on equity of -31.94% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xencor-181.17% -31.94% -22.19% Apellis Pharmaceuticals -28.83%-99.19%-25.35% SummaryApellis Pharmaceuticals beats Xencor on 9 of the 17 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$657.62M$2.76B$5.71B$9.51BDividend YieldN/A1.78%4.60%3.99%P/E Ratio-3.029.0628.0720.02Price / Sales5.21744.11459.47103.02Price / CashN/A166.2336.5558.97Price / Book0.975.188.615.88Net Income-$232.62M$30.99M$3.24B$258.50M7 Day Performance3.75%7.26%3.83%2.03%1 Month Performance8.71%15.66%10.40%12.52%1 Year Performance-56.25%-1.06%34.13%19.07% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor4.5069 of 5 stars$9.31+0.7%$28.00+200.9%-54.7%$657.62M$127.23M-3.02280Positive NewsAPLSApellis Pharmaceuticals4.2298 of 5 stars$19.91+2.4%$39.79+99.8%-46.3%$2.50B$781.37M-11.12770Upcoming EarningsXENEXenon Pharmaceuticals3.7513 of 5 stars$32.60+1.2%$54.82+68.2%-29.1%$2.50B$9.43M-10.09210Positive NewsOptions VolumeNAMSNewAmsterdam Pharma3.7852 of 5 stars$22.17+2.9%$42.89+93.5%+23.8%$2.49B$47.14M-11.794GMTXGemini TherapeuticsN/A$56.91-1.9%N/A+32.1%$2.47BN/A-56.9130BHCBausch Health Cos3.4604 of 5 stars$6.34-1.3%$7.30+15.2%+16.6%$2.34B$9.63B-57.5920,700Upcoming EarningsAGIOAgios Pharmaceuticals4.3441 of 5 stars$39.23+0.5%$58.60+49.4%-17.7%$2.27B$37.04M3.49390Upcoming EarningsAnalyst ForecastTWSTTwist Bioscience4.3689 of 5 stars$37.80-0.6%$50.40+33.3%-37.4%$2.26B$312.97M-11.63990Positive NewsINDVIndivior1.1562 of 5 stars$15.62+1.0%$17.00+8.8%+54.5%$2.15B$1.17B-50.391,051News CoverageAnalyst ForecastRXRXRecursion Pharmaceuticals1.4367 of 5 stars$5.28flat$7.00+32.6%-19.8%$2.15B$59.82M-2.98400DNLIDenali Therapeutics4.2552 of 5 stars$14.69+1.2%$33.71+129.5%-39.4%$2.13B$330.53M-5.50430News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Apellis Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives Gemini Therapeutics Alternatives Bausch Health Cos Alternatives Agios Pharmaceuticals Alternatives Twist Bioscience Alternatives Indivior Alternatives Recursion Pharmaceuticals Alternatives Denali Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XNCR Stock Alerts